Patient P-02157
Therapy response
Stable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 73 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 79 GI-04 recommended — GI Support Protocol GI-04
- Day 80 Patient declined — Not now
- Day 92 ME-01 recommended — Monitoring Escalation ME-01
- Day 93 Patient accepted — Started ME-01 in the companion
- Day 96 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 73.
Primary contributors, last 14 days
- Treatment adherence-8
- Inflammatory activity-3
What helped?
- GI Support Protocol GI-04Day 79Declined by patient
- Monitoring Escalation ME-01Day 92Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 88% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 40/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 72 and rising
- WearableSleep 5.2 h, below personal baseline
- Inflammatory signalling ↓40
- BloodInflammatory load index 61
- WearableHRV 35 ms, trending down
- Autonomic recovery ↓40
- Wearable1,818 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑20
- BloodToxicity index 52
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.7 · butyrate capacity 40/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 37 ms
- Sleep
- 5.3 h
- Steps
- 2,161
- Resting HR
- 71 bpm
Daily log: GI score 72, nutritional resilience 32, adherence 38.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02532 | 62% | S14 | — | — | 58 |
| P-02320 | 58% | S14 | NP-02 | improved | 50 |
| P-02511 | 51% | S04 | — | — | 51 |
| P-02340 | 50% | S14 | NP-02 | no change | 46 |
| P-02594 | 50% | S20 | — | — | 45 |
| P-02348 | 49% | S14 | GI-04 | improved | 49 |
| P-02372 | 48% | S14 | ME-01 | improved | 53 |
| P-02514 | 47% | S05 | ME-01 | improved | 44 |
| P-02535 | 47% | S14 | SC-12 | improved | 50 |
| P-02628 | 47% | S14 | SC-12 | improved | 47 |
| P-02571 | 46% | S11 | ME-01 | improved | 43 |
| P-02593 | 46% | S14 | ME-01 | improved | 46 |